Get your full text copy in PDF
Ingrid Hodorová, Silvia Rybárová, Peter Solár, Marián Benický, Dušan Rybár, Zuzana Kováčová, Jozef Mihalik
(Department of Anatomy, P.J. Šafárik University, Faculty of Medicine, Košice, Slovakia)
Med Sci Monit 2018; 24:5422-5426
Studies on monoamine oxidase B (MAO-B) expression in renal cell carcinoma (RCC) are lacking. This study focused on the immunohistochemical evaluation of MAO-B in RCC.
MATERIAL AND METHODS: Sixty-three RCC samples were compared on basic clinical and histopathological parameters, including histopathological type and tumor grade. RCC samples were divided according to the histopathological type into 2 groups: conventional type (51 samples) and other types (12 samples). For MAO-B detection, a standard immunohistochemical procedure was employed.
RESULTS: In healthy kidney samples, MAO-B was detected predominantly in tubules. Fifty-two cancer tissue samples were MAO-B negative and 11 tissue samples were MAO-B low positive. Enzymes were detected only in the cytoplasm. We did not find any significant correlation between the percentage of positive MAO-B specimens and nuclear grade. Additionally, Fisher’s test did not reveal any difference in numbers of positive and negative MAO-B samples between the 2 RCC types (P>0.05).
CONCLUSIONS: From our results, it was clear that MAO-B expression played no significant role in stimulation of renal cancer development. We found that MAO-B occurred only in 19% of kidney tumors and that the positivity of protein expression was low. Moreover, it seems that the disappearance of this enzyme in RCC is a consequence of replacement of healthy tissue by cancer cells. On the other hand, one can assume that the loss of MAO-B expression could be associated with severe pathological processes in the kidney.